Logo

PerkinElmer to Use Orchid Tech to Develop, Sell SNP-Diagnostic Assays

Jul 09, 2002

NEW YORK, July 9 - PerkinElmer will develop and sell fluorescence-based SNP-diagnostic assays gleaned from genotyping technology owned by Orchid Bioscience, the companies said today.

 

By taking this step, PerkinElmer cashes in an option granted by Orchid to obtain exclusive rights to its SNP-IT technology in fluorescence polarization-based reagent kits.

That agreement, struck in December 2000, gave PerkinElmer exclusive rights to sell to the products market tools based on the Orchid technology. The latest option allows PerkinElmer to concentrate on the molecular-diagnostics market, the firms said.

 

Click here for more information.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.